Bepotastine besilate
[CAS# 190786-44-8]

Identification

• Classification: API >> Antineoplastic agents >> Alkylating agent
• Name: Bepotastine besilate
• Synonyms: (+)-(S)-4-[4-[1-(4-Chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]butyric acid benzenesulfonate
• Molecular Formula: C₂₁H₂₅ClN₂O₃.C₆H₆O₃S
• Molecular Weight: 547.07
• CAS Registry Number: 190786-44-8
• EC Number: 878-395-1
• SMILES: C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O.C1=CC=C(C=C1)S(=O)(=O)O

Properties

• Solubility: 10 mM (DMSO) (Expl.)

Safety Data

• Hazard Symbols: GHS08 Warning
• Risk Statements: H361
• Safety Statements: P203-P280-P318-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Reproductive toxicity	Repr.	2	H361

Discovery and Applications

Bepotastine besilate is a second-generation antihistamine that has shown significant promise in the treatment of allergic conditions such as allergic rhinitis and urticaria. It belongs to a class of drugs known as selective histamine H1 receptor antagonists, and its primary mechanism of action involves blocking the effects of histamine, a chemical mediator that is responsible for symptoms associated with allergies, including itching, swelling, and inflammation.

The discovery of bepotastine besilate dates back to the early 2000s, with the compound being developed by the pharmaceutical company UCB. The compound was designed to have a strong affinity for the histamine H1 receptor while minimizing the sedative effects that are often associated with first-generation antihistamines. This was achieved by selecting a molecular structure that would allow bepotastine to act specifically on peripheral histamine receptors, reducing its ability to cross the blood-brain barrier and thus avoiding central nervous system side effects such as drowsiness.

Bepotastine besilate has a unique chemical structure, which includes a piperazine derivative that enhances its selective binding to histamine receptors. This structure allows it to provide effective relief from allergic symptoms without the sedating effects that are common with many older antihistamines. The compound is marketed in its besilate salt form, which improves its solubility and bioavailability, making it more effective when administered orally.

The main application of bepotastine besilate is in the treatment of allergic rhinitis, a condition characterized by symptoms such as sneezing, runny nose, and nasal congestion. It is also used to treat urticaria, commonly known as hives, which is a skin condition marked by the appearance of itchy welts. In clinical studies, bepotastine has demonstrated efficacy in reducing these symptoms, providing relief for patients suffering from allergic reactions.

Bepotastine besilate is typically administered as an oral tablet, and its efficacy has been well-documented in clinical trials. Unlike many older antihistamines, it does not cause significant sedation, making it a preferred option for individuals who need to remain alert and active throughout the day. Its favorable side effect profile, coupled with its effectiveness in controlling allergy symptoms, has led to its approval in various countries as a treatment for both allergic rhinitis and chronic urticaria.

In addition to its established uses in treating allergic conditions, there is ongoing research into the broader potential applications of bepotastine besilate. Researchers are exploring its role in treating other allergic diseases and investigating its possible use in conditions such as asthma, although further studies are needed to confirm these potential benefits.

In conclusion, bepotastine besilate is an effective and non-sedating antihistamine that has proven useful in the treatment of allergic rhinitis and chronic urticaria. Its discovery marked a significant advancement in antihistamine therapy, offering patients a safer and more effective alternative to older medications. Its favorable pharmacological profile continues to make it a valuable tool in the management of allergy-related conditions.

References

2024. Allergic Conjunctivitis Management: Update on Ophthalmic Solutions. Current Allergy and Asthma Reports, 24(6).
DOI: 10.1007/s11882-024-01150-0

2023. Design of experiment (DoE)-based formulation design of bepotastine sustained-release tablet and in vitro-in vivo pharmacokinetic correlation. Journal of Pharmaceutical Investigation, 53(2).
DOI: 10.1007/s40005-023-00611-4

2006. EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE. Drug metabolism and disposition: the biological fate of chemicals, 34(5).
DOI: 10.1124/dmd.105.007559